Mitsuno K, Agishi T, Nakazawa H, Shimada H, Higuchi Y, Matsumoto K, Kobayashi M, Arai H
Gan To Kagaku Ryoho. 1985 Aug;12(8):1612-7.
In the use of hyperthermia treatment, it is apparent from the work of other investigators that only a proportion of large clinical neoplastic tumors of substantial size and deep location can be heated to adequate temperatures (over 42 degrees c). It is therefore of major significance that we have tested the concept that OK-432 can be used as an immunoheat potentiator. A ThermaTech 2000 was used as the radio-frequency generator at 13.56 MHz, including an ancillary computer in the thermometry unit. Minor response in advanced and metastatic tumors was observed in 3 of 3 evaluable patients using OK-432. With other anticancer drugs, no change was observed in 11 of 16 patients, and progressive disease in 5 of 16. However, OK-432 has severe side effects including chills & fever, therefore improved immunoheat potentiators are desirable.
在热疗的应用中，从其他研究者的工作中可以明显看出，只有一部分体积较大且位置较深的临床肿瘤性大肿瘤能够被加热到足够的温度（超过42摄氏度）。因此，我们测试了OK-432可用作免疫热增强剂这一概念，这具有重要意义。使用ThermaTech 2000作为13.56 MHz的射频发生器，在测温单元中包括一台辅助计算机。在3例可评估的使用OK-432的患者中，观察到晚期和转移性肿瘤有轻微反应。使用其他抗癌药物时，16例患者中有11例无变化，16例中有5例病情进展。然而，OK-432有严重的副作用，包括寒战和发热，因此需要改进的免疫热增强剂。
